Commercial applications of our discoveries are covered by one or more pending United States patents. To inquire about licensing, email licensing[at]glucosegenius[dot]com.
@scottparadis I haven't looked closely enough at Loop's algo to be able to determine how easy/difficult implementation there might be, but I'm happy to support/answer questions as much as I can
I wish my dear friend Katie DiSimone could see all the touching posts being written about her from every corner of the globe. She knew what an impact she made but the outpouring of messages has been nothing short of amazing. #missingyou#payitforward#wearenotwaiting.
Woooottt!
Finally, Real movement from @LillyDiabetes !
Eli Lilly to Cut Price of Insulin by 70%, Cap Insulin Costs at $35 a Month https://t.co/VVTlKFks1J via @diaTribeNews
@Lin62866960@Savannah_Tay1 It's not just a question of availability. Many DIYers use those options because they allow for more flexibility as to devices, algorithms, and settings than commercial systems - so many people can achieve better control with less work.
“What do you love and how can we make it right for you?” #nobadfood#healthequity How can we expect success in diabetes healthcare when we don’t teach PWDs how to eat their comfort foods? @TaraTalksFood@Joyful_RDCDE @MDT_Diabetes
The Fall 2022 DiabetesMine D-Data ExChange & #Innovation Summit are on for Nov. 17-18 in SF!
#DData events connect patients/industry/HCP leaders creating new #medtech & services taking diabetes care to the next level.
Interested? Ping @[email protected] for an invite.
Healthcare providers: if you’re not familiar with automated insulin delivery systems, this offers suggestions for evaluating AID systems and some tips for working with people with diabetes to increase their optimization of these systems.
Open access: https://t.co/hKT4yNZgcb
Transmitters for 5 of the 6 devices about to be attached, side by side. From left to right:
Dexcom One
Dexcom G6
GlucoRX Aidex
Medtrum Nano
Glucomen Day
Medtrum Nano is by far the smallest device and applicator.
And the detritus after applying six CGMs.
#GBDoc#DOC
"I found the #DData22 presentations to be really insightful, and I learned an incredible amount of information! The conversations... really opened my eyes to many different aspects of #diabetes that I had not thought about before."
- E. Cornelius, Data Analyst, @T1DExchange
📣 Presentation of the primary outcome results from the CREATE Trial, which assessed open source automated insulin delivery (AID) compared to sensor-augmented pump therapy (SAPT) in adults & kids with T1D, at #ADA2022!
@DrMartindeBock1 presenting on behalf of CREATE team.
1/